




PHARMACEUTICAL 2017

RENOVARO BIOSCIENCES INC.
Rank 259 of 292





RealRate

PHARMACEUTICAL 2017

RENOVARO BIOSCIENCES INC. Rank 259 of 292

The relative strengths and weaknesses of RENOVARO BIOSCIENCES INC. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of RENOVARO BIOSCIENCES INC. compared to the market average is the variable Other Expenses, increasing the Economic Capital Ratio by 46% points. The greatest weakness of RENOVARO BIOSCIENCES INC. is the variable Assets, Current, reducing the Economic Capital Ratio by 111% points.

The company's Economic Capital Ratio, given in the ranking table, is -238%, being 241% points below the market average of 2.9%.

Input Variable	Value in 1000 USD
Assets, Current	732
Cost of Goods Sold	0
Intangible Assets	136
Liabilities, Current	1,508
Liabilities, Non-Current	0
Other Assets	2.6
Other Compr. Net Income	0
Other Expenses	-333
Other Liabilities	0
Other Net Income	-77
Other Revenues	43
Property and Equipment	0
Research and Development	804
Selling, General and Administrative Expense	1,230

Output Variable	Value in 1000 USD
Assets	871
Liabilities	1,508
Expenses	1,701
Revenues	43
Stockholders Equity	-637
Net Income	-1,735
Comprehensive Net Income	-1,735
Economic Capital Ratio	-238%